Want to see JP:4592 full AI Analyst Report?
Top Page
SanBio Co
(4592)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥915.00
▼(-8.32% Downside)
Action:Reiterated
Date:09/20/26
The score is driven primarily by weak financial performance (no revenue, ongoing large losses, and persistent cash burn), which creates high dependence on future commercialization and financing. Technicals add modest pressure due to negative MACD and the price sitting below key longer-term moving averages. Valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
Improved balance-sheet capacity
The sharp increase in equity and generally manageable recent leverage provide a stronger solvency base for continued development activity. Although profitability is absent, this balance-sheet improvement can support operations and reduce immediate financial strain over the next several quarters.
Negative Factors
No established revenue base
Persistent zero revenue means SanBio has not yet demonstrated commercial product demand or recurring operating income. The company therefore remains dependent on successful development and eventual approval of its therapies, making future earnings highly uncertain over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance-sheet capacity
The sharp increase in equity and generally manageable recent leverage provide a stronger solvency base for continued development activity. Although profitability is absent, this balance-sheet improvement can support operations and reduce immediate financial strain over the next several quarters.
Read all positive factors
SanBio Co (4592) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥79.54B
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth5.71%
CountryJP
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.94
Shares Outstanding78,058,880
10 Day Avg. Volume1,541,620
30 Day Avg. Volume1,080,603
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,450.00Price Target Upside45.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-44.27
Revenue Forecast (FY)¥2.66B
SanBio Co Business Overview & Revenue Model
Company Description
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has comp...
How the Company Makes Money
SanBio’s primary economic model is typical of a clinical-stage regenerative medicine/biotech company: it funds operations mainly through (1) progressing proprietary cell therapy candidates toward regulatory approval and eventual product sales, and...
SanBio Co Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jan 2026 | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.17M | -8.05M | -9.37M | -14.50M | -24.61M | -132.47M |
| EBITDA | -3.41B | -4.20B | -2.98B | -2.50B | -4.62B | -4.37B |
| Net Income | -3.15B | -3.84B | -2.88B | -2.64B | -5.56B | -4.68B |
Balance Sheet | ||||||
| Total Assets | 14.52B | 15.62B | 3.45B | 5.05B | 7.05B | 5.51B |
| Cash, Cash Equivalents and Short-Term Investments | 14.00B | 15.08B | 2.92B | 4.45B | 6.73B | 4.56B |
| Total Debt | 1.18B | 1.24B | 397.00M | 665.00M | 933.00M | 2.52B |
| Total Liabilities | 1.84B | 2.02B | 1.68B | 2.25B | 2.62B | 3.48B |
| Stockholders Equity | 12.68B | 13.60B | 1.76B | 2.79B | 4.43B | 2.04B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -3.84B | -3.62B | -4.79B | -7.46B | -6.61B |
| Operating Cash Flow | 0.00 | -3.81B | -3.62B | -4.78B | -7.45B | -6.57B |
| Investing Cash Flow | 0.00 | -231.04M | -4.27M | -19.03M | -10.10M | -66.26M |
| Financing Cash Flow | 0.00 | 16.01B | 2.10B | 2.38B | 9.46B | -1.47B |
SanBio Co Technical Analysis
Positive
998.00
Price Trends
958.38
Positive
1060.23
Negative
1499.83
Negative
Market Momentum
-2.54
Negative
56.76
Neutral
30.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4592, the sentiment is Positive. The current price of 998 is above the 20-day moving average (MA) of 937.10, above the 50-day MA of 958.38, and below the 200-day MA of 1499.83, indicating a neutral trend. The MACD of -2.54 indicates Negative momentum. The RSI at 56.76 is Neutral, neither overbought nor oversold. The STOCH value of 30.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4592.
SanBio Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥40.93B | 60.89 | ― | ― | -47.32% | ― | |
46 Neutral | ¥32.20B | -73.15 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥13.51B | -28.32 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥8.34B | -7.29 | ― | ― | -56.16% | 3.12% | |
43 Neutral | ¥79.54B | -21.36 | -37.79% | ― | ― | 5.71% | |
40 Underperform | ¥10.28B | -5.52 | ― | ― | ― | 4.68% |
* Healthcare Sector Average
JP:4592
SanBio Co
1,019.00
-2,831.00
-73.53%
JP:4593
Healios KK
302.00
-166.00
-35.47%
JP:4599
StemRIM Inc.
164.00
-125.00
-43.25%
JP:4978
ReproCELL Inc.
130.00
-45.00
-25.71%
JP:7774
Japan Tissue Engineering Co., Ltd.
793.00
307.00
63.17%
JP:7776
CellSeed Inc.
211.00
-255.00
-54.72%
SanBio Co Corporate Events
SanBio outlines Q2 results and global regenerative medicine ambitions
Sep 17, 2026
SanBio Company Limited has released its financial results for the second quarter of the fiscal year ending January 31, 2027, outlining performance in the first half and key operational progress. The company also presented its future outlook, empha...
SanBio Narrows Interim Loss on Cost Timing and FX Gains, Keeps Full-Year Outlook
Sep 15, 2026
SanBio reported that its second-quarter results for the fiscal year ending January 31, 2027 showed a significantly narrower loss than previously forecast, driven mainly by lower expenses and a reclassification of certain manufacturing-related cost...
SanBio Posts Continued Losses but Maintains Strong Equity Base as It Invests in Regenerative Medicine
Sep 15, 2026
SanBio Co., Ltd., listed on the Tokyo Stock Exchange, is a biotechnology firm specializing in regenerative medicine and advanced cell-based therapies. Operating under Japanese GAAP, the company remains in a pre-commercial or early-commercial phase...
SanBio books forex gains, financing costs and deferred taxes in Q2
Sep 14, 2026
SanBio Co., Ltd. reported notable non-operating items in the second quarter of its fiscal year ending January 31, 2027, including a foreign exchange gain of ¥185 million tied mainly to foreign currency loans to a subsidiary, partly offset by ...
SanBio Shifts AKUUGO Manufacturing to Japan After Minaris U.S. Plant Closure
Sep 7, 2026
SanBio has been informed that Minaris Advanced Therapies LLC will close its Mountain View, California, U.S. facility, which currently performs upstream manufacturing processes for AKUUGO. In response, SanBio plans to transfer these upstream operat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.